Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aclarion, Inc. - Warrant (NQ:ACONW)

0.0368 +0.0037 (+11.18%)
Streaming Delayed Price Updated: 10:05 AM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aclarion, Inc. - Warrant

News headline image
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st
Via ACCESSWIRE
News headline image
Aclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV
Via ACCESSWIRE
News headline image
Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor
Via ACCESSWIRE
News headline image
Aclarion Announces Participation at the NASS 37th Annual Meeting
Via ACCESSWIRE
News headline image
John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor
Via ACCESSWIRE
News headline image
Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain
Via ACCESSWIRE
News headline image
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan
Via ACCESSWIRE
News headline image
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan
Initial findings from the EVAL study are expected to be released in Q4 2022 
From Aclarion Inc.
Via AccessWire
News headline image
Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain
Superior Clinical Outcomes for NociscanTM Proving to be Durable at Two Years 
From Aclarion Inc.
Via AccessWire
News headline image
Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering
SAN MATEO, CA / ACCESSWIRE / April 26, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON) (NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy... 
From Aclarion Inc.
Via AccessWire
Topics Artificial Intelligence Regulatory Compliance
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.